Delivery Order SPE2DB20D1100-SPE2DB25FD9M3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $1,214.32 with a firm fixed price. The contract, which was competitively awarded without a set-aside designation, has an ultimate completion date of August 14, 2025, and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The place of performance is listed as the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $58,788.32 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on September 12, 2025, with completion anticipated by September 15, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement supporting military healthcare operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,958.07 to supply Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $2,270.22 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $41,766.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, which is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), carries an ultimate completion date of August 22, 2025. This award was competitively granted with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors, valued at $7,769.28 under firm fixed pricing. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $10,789.86 under a firm fixed price contract. The award was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside, competitively awarded procurement. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9M3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,401.87 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing comprehensive medical supply support to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The SPE2DX global pharmaceutical support vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha is a PCSK9 inhibitor used in cardiovascular disease management, demonstrating AmerisourceBergen's role in delivering specialty medications across multiple therapeutic domains to support federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/8/25 |